HK Stock Market Move | METIS TECHBIO-P (07666) rose nearly 7% in morning trading; AiLNP platform gains endorsement from an international pharmaceutical company, and the platform's value is expected to continue to be reflected.

METIS TECHBIO-P (07666) rose nearly 7% in morning trading. As of press time, it was up 5.96% at HK$11.56, with turnover of HK$38.7959 million. On the news front, Metis TechBio recently announced the signing of a strategic collaboration with Eli Lilly to jointly advance next-generation tissue-specific LNP delivery technology. Metis TechBio will leverage its NanoForge-driven AiLNP platform to develop next-generation LNP delivery technology, while Eli Lilly will contribute drug discovery, development, and commercialization resources to advance the collaboration. Metis TechBio will receive an upfront payment of over US$10 million, milestone payments of up to US$1.1 billion, and tiered royalties. HAITONG INT'L believes that the company's collaboration with global leading pharmaceutical company Eli Lilly further validates the differentiated value of the company's AiLNP delivery technology and NanoForge platform, and provides endorsement from a major international pharmaceutical company. Demand for extrahepatic delivery in the pharmaceutical industry is expected to continue to be released, and the company's AiLNP technology platform has established a certain first-mover advantage, with the platform's value expected to continue to be reflected.